September 12, 2024 Steve Gleason Welcomes Guests to Day 2 of #CGIC24 Former NFL player and ALS patient advocate welcomes attendees to the second day of C-Path’s Global Impact Conference.
May 23, 2024 C-Path’s RDCA-DAP Webinar, “The Use and Development of DHTs with Patient Advocacy Groups” a Hit, with Keynote, Patient Advocacy Panel, and Engaged QAs Critical Path Institute’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), part of C-Path's Rare...
May 22, 2024 C-Path Roundtable: Help4HD Unites to Discuss Advancements in Huntington’s Disease Treatments "My husband passed away with no therapies, no treatments that worked for him, and it took away his quality of life...
April 23, 2024 Clinical Outcome Assessment — Initial Public Discussion In this presentation from C-Path's rare and orphan disease program, you will see...
December 2, 2020 COVID-19: Risk Assessment and Mitigation Strategies for the Collection of PRO Data through Clinical Sites – Lessons Learned This webinar provides an update from sponsors and eCOA providers as they discuss lessons learned from managing clinical trials tha
May 16, 2019 Best Practices for Avoiding Paper Backup When Implementing Electronic Approaches to Patient-Reported Outcome Data Collection in Clinical Trials (May 16, 2019) This webinar provides an overview of the issues related to the use of paper backups in studies for which PRO data is collected ele
In Recognition of 10th Anniversary, Raymond Woosley and Janet Woodcock Address CPAD Consortium’s 2018 Annual Meeting and Regulatory Science Workshop At its 10th Annual Meeting and Regulatory Science Workshop, November 13, 2018, in Bethesda, MD, C-Path’s Critical Path for Alzhe
May 10, 2018 Training on the Use of Technology to Collect Patient-Reported Outcome Data Electronically in Clinical Trials: Best Practice Recommendations from the ePRO Consortium (May 10, 2018) This webinar provides a recommended framework for training end users, including site staff and study participants, on the use of e
FDA CDER Regulatory Science: The Importance of Partnership and Consortia Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research within the United States Food and Drug Administration,
June 6, 2017 Selection of and Evidentiary Considerations for Wearable Devices and Their Measurements for Use in Regulatory Decision Making: Recommendations from the ePRO Consortium This webinar provides a recommended framework for the selection and evaluation of wearable devices and their measurements for use
